

Clean Copy of All Pending Claims

1. A method of treating permeability failure in a subject, comprising: introducing into said subject a peritoneal dialysis fluid which includes a specific inhibitor of a PKC, thereby treating said subject.
2. The method of claim 1, wherein said specific inhibitor is a specific inhibitor of PKC β .
3. The method of claim 1, wherein said specific inhibitor is selected from the group consisting of: a specific inhibitor of a PKC β , a specific inhibitor of PKC γ , and a specific inhibitor of PKC δ .
5. The method of claim 1, wherein said specific inhibitor is an inhibitor of PKC $\beta 1$.
6. The method of claim 2, wherein said inhibitor is a bis (indolyl) maleimide.
7. The method of claim 6, wherein said inhibitor is LY333531.
8. The method of claim 7, wherein said LY333531 is present in said dialysis fluid at about 1-1,000 nM.
9. The method of claim 1, wherein said dialysis fluid has a concentration of glucose of about 200nM.
10. The method of claim 1, wherein said subject has previously received peritoneal dialysis.
11. The method of claim 1, wherein said subject has been a peritoneal dialysis patient for at least 2 to 24 months.

12. The method of claim 1, wherein said subject has already developed permeability disjunction.
13. The method of claim 1, wherein said subject has not yet developed permeability disjunction.
14. The method of claim 1, wherein said subject is at risk for renal failure.
15. The method of claim 14, wherein said subject is in end-stage renal failure.
16. A peritoneal dialysis fluid comprising a specific inhibitor of a PKC.
18. The dialysis fluid of claim 16, wherein said specific inhibitor is an inhibitor of PKC β .
19. The dialysis fluid of claim 18, wherein said inhibitor is a bis (indolyl) maleimide.
20. The dialysis fluid of claim 19, wherein said inhibitor is LY333531.
21. The dialysis fluid of claim 20, wherein said LY333531 is present in said dialysis fluid at about 1-1,000 nM.
22. The dialysis fluid of claim 16, wherein said dialysis fluid has a concentration of glucose of about 200nM.
23. A method of making an improved peritoneal dialysis fluid, comprising: providing a peritoneal dialysis fluid; and adding to that fluid a specific inhibitor of a PKC, to thereby provide an improved dialysis fluid.
24. A method of making an improved peritoneal dialysis fluid, comprising: providing a peritoneal dialysis fluid and adding LY333531 to the dialysis fluid.

25. A method of treating a subject, comprising: introducing into said subject a peritoneal dialysis fluid which includes an inhibitor of PKC β , an inhibitor of PKC γ , or an inhibitor of PKC δ , thereby treating said subject.

26. A method of treating a subject, comprising: introducing into said subject a peritoneal dialysis fluid which includes an inhibitor of PKC β .

27. A peritoneal dialysis fluid comprising an inhibitor of PKC β , an inhibitor of PKC δ , or an inhibitor of PKC γ .

28. A peritoneal dialysis fluid comprising an inhibitor of PKC β .

29. A peritoneal dialysis fluid comprising LY333531.
